Do analysts prefer DSY or DRMA?

Dermata Therapeutics has a consensus target price of $10.00, indicating a potential upside of 813.24%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dermata Therapeutics is more favorable than Big Tree Cloud. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Big Tree Cloud 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, DSY or DRMA?

Dermata Therapeutics has lower revenue, but higher earnings than Big Tree Cloud. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Big Tree Cloud $2.56M 8.92 -$32.53M N/A N/A Dermata Therapeutics N/A N/A -$7.56M -$5.31 N/A

Is DSY or DRMA more profitable?

Big Tree Cloud's return on equity of 0.00% beat Dermata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Big Tree Cloud N/A N/A N/A Dermata Therapeutics N/A -127.91% -105.05%

Does the media prefer DSY or DRMA?

In the previous week, Dermata Therapeutics had 1 more articles in the media than Big Tree Cloud. MarketBeat recorded 2 mentions for Dermata Therapeutics and 1 mentions for Big Tree Cloud. Dermata Therapeutics' average media sentiment score of 0.42 beat Big Tree Cloud's score of 0.00 indicating that Dermata Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Big Tree Cloud 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dermata Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer NHTC or DRMA?

Dermata Therapeutics has a consensus price target of $10.00, indicating a potential upside of 813.24%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dermata Therapeutics is more favorable than Natural Health Trends. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Health Trends 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend MTEX or DRMA?

Dermata Therapeutics has a consensus target price of $10.00, indicating a potential upside of 813.24%. Given Dermata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Dermata Therapeutics is more favorable than Mannatech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Dermata Therapeutics (DRMA) Competitors

$1.10 -0.01 (-0.45%)

As of 03:41 PM Eastern

Compare

DRMA vs. DSY, NHTC, NAII, MTEX, and SNYR

Should you buy Dermata Therapeutics stock or one of its competitors? MarketBeat compares Dermata Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dermata Therapeutics include Big Tree Cloud (DSY), Natural Health Trends (NHTC), Natural Alternatives International (NAII), Mannatech (MTEX), and Synergy CHC (SNYR). These companies are all part of the "personal care products" industry.

How does Dermata Therapeutics compare to Big Tree Cloud?

Big Tree Cloud (NASDAQ:DSY) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap consumer staples companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

In the previous week, Dermata Therapeutics had 1 more articles in the media than Big Tree Cloud. MarketBeat recorded 2 mentions for Dermata Therapeutics and 1 mentions for Big Tree Cloud. Dermata Therapeutics' average media sentiment score of 0.42 beat Big Tree Cloud's score of 0.00 indicating that Dermata Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Big Tree Cloud	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dermata Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Big Tree Cloud has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Dermata Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

60.2% of Big Tree Cloud shares are held by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are held by institutional investors. 34.1% of Big Tree Cloud shares are held by insiders. Comparatively, 21.9% of Dermata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dermata Therapeutics has a consensus target price of $10.00, indicating a potential upside of 813.24%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dermata Therapeutics is more favorable than Big Tree Cloud.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Big Tree Cloud	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Big Tree Cloud's return on equity of 0.00% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Big Tree Cloud	N/A	N/A	N/A
Dermata Therapeutics	N/A	-127.91%	-105.05%

Dermata Therapeutics has lower revenue, but higher earnings than Big Tree Cloud.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Big Tree Cloud	$2.56M	8.92	-$32.53M	N/A	N/A
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A

Summary

Dermata Therapeutics beats Big Tree Cloud on 7 of the 12 factors compared between the two stocks.

How does Dermata Therapeutics compare to Natural Health Trends?

Natural Health Trends (NASDAQ:NHTC) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap consumer staples companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Natural Health Trends has higher revenue and earnings than Dermata Therapeutics. Natural Health Trends is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natural Health Trends	$39.78M	0.38	-$880K	-$0.16	N/A
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A

Dermata Therapeutics has a net margin of 0.00% compared to Natural Health Trends' net margin of -4.51%. Natural Health Trends' return on equity of -8.00% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natural Health Trends	-4.51%	-8.00%	-4.58%
Dermata Therapeutics	N/A	-127.91%	-105.05%

10.1% of Natural Health Trends shares are owned by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are owned by institutional investors. 12.9% of Natural Health Trends shares are owned by insiders. Comparatively, 21.9% of Dermata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Dermata Therapeutics has a consensus price target of $10.00, indicating a potential upside of 813.24%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dermata Therapeutics is more favorable than Natural Health Trends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natural Health Trends	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Dermata Therapeutics had 2 more articles in the media than Natural Health Trends. MarketBeat recorded 2 mentions for Dermata Therapeutics and 0 mentions for Natural Health Trends. Dermata Therapeutics' average media sentiment score of 0.42 beat Natural Health Trends' score of 0.00 indicating that Dermata Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Natural Health Trends	Neutral
Dermata Therapeutics	Neutral

Natural Health Trends has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market. Comparatively, Dermata Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Summary

Dermata Therapeutics beats Natural Health Trends on 8 of the 15 factors compared between the two stocks.

How does Dermata Therapeutics compare to Natural Alternatives International?

Dermata Therapeutics (NASDAQ:DRMA) and Natural Alternatives International (NASDAQ:NAII) are both small-cap consumer staples companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Dermata Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market. Comparatively, Natural Alternatives International has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

Dermata Therapeutics has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Natural Alternatives International's return on equity of -12.21% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-127.91%	-105.05%
Natural Alternatives International	-10.13%	-12.21%	-5.30%

Dermata Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 813.24%. Given Dermata Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Dermata Therapeutics is more favorable than Natural Alternatives International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Dermata Therapeutics has higher earnings, but lower revenue than Natural Alternatives International. Natural Alternatives International is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A
Natural Alternatives International	$141.87M	0.10	-$13.57M	-$2.39	N/A

8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 32.4% of Natural Alternatives International shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by insiders. Comparatively, 20.8% of Natural Alternatives International shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Dermata Therapeutics had 2 more articles in the media than Natural Alternatives International. MarketBeat recorded 2 mentions for Dermata Therapeutics and 0 mentions for Natural Alternatives International. Natural Alternatives International's average media sentiment score of 1.00 beat Dermata Therapeutics' score of 0.42 indicating that Natural Alternatives International is being referred to more favorably in the news media.

Company	Overall Sentiment
Dermata Therapeutics	Neutral
Natural Alternatives International	Positive

Summary

Dermata Therapeutics beats Natural Alternatives International on 9 of the 15 factors compared between the two stocks.

How does Dermata Therapeutics compare to Mannatech?

Mannatech (NASDAQ:MTEX) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Dermata Therapeutics has lower revenue, but higher earnings than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04M	0.09	-$15.21M	-$6.71	N/A
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A

In the previous week, Dermata Therapeutics had 2 more articles in the media than Mannatech. MarketBeat recorded 2 mentions for Dermata Therapeutics and 0 mentions for Mannatech. Dermata Therapeutics' average media sentiment score of 0.42 beat Mannatech's score of 0.00 indicating that Dermata Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Mannatech	Neutral
Dermata Therapeutics	Neutral

Dermata Therapeutics has a consensus target price of $10.00, indicating a potential upside of 813.24%. Given Dermata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Dermata Therapeutics is more favorable than Mannatech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

13.0% of Mannatech shares are held by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are held by institutional investors. 47.5% of Mannatech shares are held by insiders. Comparatively, 21.9% of Dermata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Dermata Therapeutics has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Dermata Therapeutics' return on equity of -127.91% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mannatech	-11.97%	-2,383.34%	-40.24%
Dermata Therapeutics	N/A	-127.91%	-105.05%

Mannatech has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Comparatively, Dermata Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

Summary

Dermata Therapeutics beats Mannatech on 10 of the 15 factors compared between the two stocks.

How does Dermata Therapeutics compare to Synergy CHC?

Synergy CHC (NASDAQ:SNYR) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap consumer staples companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Dermata Therapeutics has lower revenue, but higher earnings than Synergy CHC. Dermata Therapeutics is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synergy CHC	$30.38M	0.08	-$12.34M	-$1.40	N/A
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A

Synergy CHC has a beta of -0.14, meaning that its stock price is 114% less volatile than the broader market. Comparatively, Dermata Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

Synergy CHC currently has a consensus price target of $6.25, suggesting a potential upside of 3,656.01%. Dermata Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 813.24%. Given Synergy CHC's higher probable upside, equities analysts plainly believe Synergy CHC is more favorable than Dermata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synergy CHC	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

8.7% of Dermata Therapeutics shares are held by institutional investors. 32.9% of Synergy CHC shares are held by company insiders. Comparatively, 21.9% of Dermata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Dermata Therapeutics has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of 0.00% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synergy CHC	-60.02%	N/A	-30.30%
Dermata Therapeutics	N/A	-127.91%	-105.05%

In the previous week, Dermata Therapeutics had 2 more articles in the media than Synergy CHC. MarketBeat recorded 2 mentions for Dermata Therapeutics and 0 mentions for Synergy CHC. Dermata Therapeutics' average media sentiment score of 0.42 beat Synergy CHC's score of 0.00 indicating that Dermata Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Synergy CHC	Neutral
Dermata Therapeutics	Neutral

Summary

Synergy CHC beats Dermata Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Dermata Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRMA vs. The Competition

Export

Metric	Dermata Therapeutics	Personal Care Products Industry	Consumer Staples Sector	NASDAQ Exchange
Market Cap	$4.39M	$22.80B	$16.13B	$12.94B
Dividend Yield	N/A	4.27%	3.20%	10.20%
P/E Ratio	-0.21	15.64	14.04	24.78
Price / Sales	N/A	12.81	264,297.10	108.19
Price / Cash	N/A	17.43	56.22	37.44
Price / Book	0.50	2.97	4.96	6.43
Net Income	-$7.56M	$1.08B	$838.30M	$347.27M
7 Day Performance	1.86%	1.02%	0.13%	2.54%
1 Month Performance	-18.28%	-2.47%	0.05%	-1.00%
1 Year Performance	-82.59%	-17.86%	12.96%	23.33%

Dermata Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRMA Dermata Therapeutics	2.8302 of 5 stars	$1.10 -0.5%	$10.00 +813.2%	-82.5%	$4.39M	N/A	N/A	8
DSY Big Tree Cloud	0.3404 of 5 stars	$3.43 -4.2%	N/A	-79.9%	$16.29M	$2.56M	N/A	82	Gap Down
NHTC Natural Health Trends	0.7009 of 5 stars	$1.65 -8.3%	N/A	-64.9%	$14.16M	$39.78M	N/A	140	High Trading Volume
NAII Natural Alternatives International	0.8312 of 5 stars	$2.25 -3.2%	N/A	-35.9%	$14.10M	$129.86M	N/A	290
MTEX Mannatech	0.8668 of 5 stars	$5.07 flat	N/A	-40.9%	$9.79M	$108.04M	N/A	250

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRMA) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dermata Therapeutics (DRMA) Competitors

DRMA vs. DSY, NHTC, NAII, MTEX, and SNYR

How does Dermata Therapeutics compare to Big Tree Cloud?

Summary

How does Dermata Therapeutics compare to Natural Health Trends?

Summary

How does Dermata Therapeutics compare to Natural Alternatives International?

Summary

How does Dermata Therapeutics compare to Mannatech?

Summary

How does Dermata Therapeutics compare to Synergy CHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRMA vs. The Competition

Dermata Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dermata Therapeutics (DRMA) Competitors

DRMA vs. DSY, NHTC, NAII, MTEX, and SNYR

How does Dermata Therapeutics compare to Big Tree Cloud?

Does the media prefer DSY or DRMA?

Which has more risk & volatility, DSY or DRMA?

Do institutionals and insiders believe in DSY or DRMA?

Do analysts prefer DSY or DRMA?

Is DSY or DRMA more profitable?

Which has better earnings and valuation, DSY or DRMA?

Summary

How does Dermata Therapeutics compare to Natural Health Trends?

Which has stronger valuation and earnings, NHTC or DRMA?

Is NHTC or DRMA more profitable?

Do insiders & institutionals hold more shares of NHTC or DRMA?

Do analysts prefer NHTC or DRMA?

Does the media refer more to NHTC or DRMA?

Which has more volatility and risk, NHTC or DRMA?

Summary

How does Dermata Therapeutics compare to Natural Alternatives International?

Which has more risk and volatility, DRMA or NAII?

Is DRMA or NAII more profitable?

Do analysts recommend DRMA or NAII?

Which has stronger valuation and earnings, DRMA or NAII?

Do institutionals and insiders have more ownership in DRMA or NAII?

Does the media favor DRMA or NAII?

Summary

How does Dermata Therapeutics compare to Mannatech?

Which has stronger earnings and valuation, MTEX or DRMA?

Does the media favor MTEX or DRMA?

Do analysts recommend MTEX or DRMA?

Do institutionals and insiders have more ownership in MTEX or DRMA?

Is MTEX or DRMA more profitable?

Which has more risk and volatility, MTEX or DRMA?

Summary

How does Dermata Therapeutics compare to Synergy CHC?

Which has preferable valuation & earnings, SNYR or DRMA?

Which has more risk and volatility, SNYR or DRMA?

Do analysts rate SNYR or DRMA?

Do institutionals & insiders hold more shares of SNYR or DRMA?

Is SNYR or DRMA more profitable?

Does the media refer more to SNYR or DRMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRMA vs. The Competition

Dermata Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools